59
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

, , , , , , , , & show all
Pages 393-398 | Published online: 22 Apr 2010

REFERENCES

  • World Health Statistics 2006. World Health Organization 2006. Retrieved December 1, 2007, from http://www.who.int/whosis/whostat2006/en/index.html.
  • Halmos, B.; Boiselle, P.M.; Karp, D.D. Lung cancer. Prim Care Update Ob Gyns 2003, 10, 87–94.
  • Yamaguchi, N.; Mochizuki-Kobayashi, Y.; Utsunomiya, O. Quantitative relationship between cumulative cigarette consumption and lung cancer mortality in Japan. Int J Epidemiol 2000, 29(6), 963–968.
  • Gledovic, Z.; Bojovic, O.; Pekmezovic, T. The pattern of lung cancer mortality in Montenegro. Eur J Cancer Prev 2003, 12(5), 373–376.
  • Sant, M.; Aareleid, T.; Berrino, F. EUROCARE-3: survival of cancer patients diagnosed 1990–1994. Results and commentary. Ann Oncol 2003, 14(Suppl. 5), v61–v118.
  • Blumenschein, G.; Heymach, J.V. Angiogenesis inhibitors for lung cancer: clinical developments and future directions. J Thorac Oncol 2006, 1(7), 744–748.
  • Sandler, A.B.; Gray, R.; Brahmer, J.; Dowlati, A.; Schiller, J.H.; Perry, M.C.; Johnson, D.H. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an eastern cooperative oncology group (ECOG) trial – E4599. J Clin Oncol 2005, 23(Suppl.1), 16S. (Abstract no. 4).
  • Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285, 1182–1186.
  • Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175, 409–416.
  • Folkman, J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82(1), 4–6.
  • Poon, R.T.; Fan, S.; Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19, 1207–1225.
  • Kondo, S.; Asano, M.; Matsuo, K.; Ohmori, I.; Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994, 1221, 211–214.
  • Yamamoto, Y.; Toi, M.; Kondo, S.; Matsumoto, T.; Suzuki, H.; Kitamura, M.; Tsuruta, K.; Taniguchi, T.; Okamoto, A.; Mori, T.; Yoshida, M.; Ikeda, T.; Tominaga, T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996, 2, 821–826.
  • Bremnes, M.R.; Camps, C.; Sirera, R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006, 51, 143–158.
  • World Health Organization. International Histological Classification of Tumours, 2nd edition. Geneva: World Health Organization, 1969–1981. Berlin, Germany: Springer-Verlag, 1988–Present.
  • Greene, F.L.; Page, D.L.; Fleming, I.D.; Fritz, A.; Balch, C.M.; Haller, D.G.; Morrow, M. American Joint Committee on Cancer Staging Manual, 6th edition. Philadelphia, PA: Springer, 2002.
  • Imoto, H.; Osaki, T.; Taga, S.; Ohgami, A.; Ichiyoshi, Y.; Yasumoto, K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115, 1007–1014.
  • Laack, E.; Köhler, A.; Kugler, C.; Dierlamm, T.; Knuffmann, C.; Vohwinkel, G.; Niestroy, A.; Dahlmann, N.; Peters, A.; Berger, J.; Fiedler, W.; Hossfeld, D.K. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002, 13, 1550–1557.
  • Trape, J.; Buxo, J.; de Olaguer, J.P. Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. Clin Chem 2003, 49, 523–525.
  • Kaya, A.; Ciledag, A.; Gulbay, B.E.; Poyraz, B.M.; Celik, G.; Sen, E.; Savas, H.; Savas, I. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Resp Med 2004, 98, 632–636.
  • Hasegawa, Y.; Takanashi, S.; Okudera, K.; Kumagai, M.; Hayashi, A.; Morimoto, T.; Okumura, K. Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med J 2005, 44(1), 26–34.
  • Suzuki, M.; Iizasa, T.; Ko, E.; Baba, M.; Saitoh, Y.; Shibuya, K.; Sekine, Y.; Yoshida, S.; Hiroshima, K.; Fujisawa, T. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002, 35, 29–34.
  • Ilhan, N.; Ilhan, N.; Deveci, F. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 2004, 37, 840–845.
  • Katsabeki-Katsafli, A.; Kerenidi, T.; Kostikas, K.; Dalaveris, E.; Kiripoulos, T.S.; Gogou, E.; Papaioannou, A.I.; Gourgoulianis, K.I. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer 2008, 60, 271–276.
  • Dalaveris, E.; Kerenidi, T.; Katsabeki-Katsafli, A.; Kiripoulos, T.S.; Tanou, K.; Gourgoulianis, K.I.; Kostikas, K. VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2009, 64, 219–225.
  • Wasada, T.; Kawahara, R.; Katsumori, K.; Naruse, M.; Omori, Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998, 46, 27–30.
  • Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843–845.
  • Matsuyama, W.; Hashiguchi, T.; Mizoguchi, A.; Iwami, F.; Kawabata, M.; Arimura, K.; Osame, M. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000, 118, 948–951.
  • Mall, J.W.; Schwenk, W.; Philipp, A.W.; Meyer-Kipker, C.; Mall, W.; Muller, J.; Pollmann, C. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 2002, 7(2), 99–102.
  • Tamura, M.; Ohta, Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003, 98, 1217–1222.
  • Tamura, M.; Oda, M.; Matsumoto, I.; Tsunezuka, Y.; Kawakami, K.; Ohta, Y.; Watanabe, G. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004, 11, 928–933.
  • Shimanuki, Y.; Takahashi, K.; Cui, R.; Hori, S.; Takahashi, F.; Miyamoto, H.; Fukurchi, Y. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005, 183(1), 29–42.
  • Brattstrom, D.; Bergqvist, M.; Hesselius, P.; Larsson, A.; Wagenius, G.; Brodin, O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004, 43, 55–62.
  • Choi, J.H.; Kim, H.C.; Lim, H.Y.; Nam, D.K.; Kim, H.S.; Yi, J.W.; Chun, M.; Oh, Y.T.; Kang, S.; Park, K.J.; Hwang, S.C.; Lee, Y.H.; Hahn, M.H. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001, 33, 171–179.
  • Salven, P.; Routsalainen, T.; Mattson, K.; Joensuu, H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998, 17, 144–146.
  • Brattström, D.; Bergqvist, M.; Hesselius, P.; Larsson, A.; Lamberg, K.; Wernlund, J.; Brodin, O.; Wagenius, G. Elevated preoperative serum levels of angiogenic cytokines correlate larger primary tumours and poorer survival in nonsmall cell lung cancer patients. Lung Cancer 2002, 37, 57–63.
  • Johnson, P.H.; Kim, E.S. Update on approaches to the treatment of advanced non-small-cell lung cancer. Oncology (Special Edition) 2005, 8, 133–137.
  • Herbst, R.S. Established and promising salvage therapies for patients with advanced non-small-cell lung cancer. Oncology (Special Edition) 2005, 8, 141–146.
  • Hormbrey, E.; Gillespie, P.; Turner, K.; Han, C.; Roberts, A.; McGrouther, D.; Harris, A.L. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002, 19, 651–663.
  • Jelkmann, W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001, 46(4), 617–623.
  • Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006, 312, 1171–1174.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.